Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




May
07
Today In Oncology
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study
Promising Signal Only ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
AI Pathology Framework for Biological Understanding of Tumors
AI Model Enables Earlier Detection of Pancreatic Cancer on Routine CT Scans
Breast Density Reduction: Endoxifen vs Tamoxifen
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo